Capital Investment Services of America Inc. Grows Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Capital Investment Services of America Inc. increased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 1.9% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 39,534 shares of the company's stock after purchasing an additional 739 shares during the period. IDEXX Laboratories accounts for 1.7% of Capital Investment Services of America Inc.'s holdings, making the stock its 28th biggest holding. Capital Investment Services of America Inc.'s holdings in IDEXX Laboratories were worth $16,602,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in IDXX. Empowered Funds LLC increased its stake in IDEXX Laboratories by 10.2% in the 4th quarter. Empowered Funds LLC now owns 1,443 shares of the company's stock worth $597,000 after acquiring an additional 133 shares during the last quarter. Kestra Private Wealth Services LLC increased its stake in IDEXX Laboratories by 7.8% in the 4th quarter. Kestra Private Wealth Services LLC now owns 1,923 shares of the company's stock worth $795,000 after acquiring an additional 139 shares during the last quarter. Avestar Capital LLC increased its stake in IDEXX Laboratories by 5.9% in the 4th quarter. Avestar Capital LLC now owns 804 shares of the company's stock worth $332,000 after acquiring an additional 45 shares during the last quarter. Asset Management One Co. Ltd. increased its stake in IDEXX Laboratories by 6.1% in the 4th quarter. Asset Management One Co. Ltd. now owns 52,844 shares of the company's stock worth $21,927,000 after acquiring an additional 3,057 shares during the last quarter. Finally, Vontobel Holding Ltd. increased its stake in IDEXX Laboratories by 90.1% in the 4th quarter. Vontobel Holding Ltd. now owns 418,563 shares of the company's stock worth $173,051,000 after acquiring an additional 198,404 shares during the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Wall Street Zen cut IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Friday, May 30th. Stifel Nicolaus boosted their price objective on IDEXX Laboratories from $460.00 to $510.00 and gave the stock a "hold" rating in a research note on Monday, May 19th. Leerink Partners boosted their price objective on IDEXX Laboratories from $515.00 to $580.00 and gave the stock an "outperform" rating in a research note on Wednesday. Finally, Morgan Stanley boosted their price objective on IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a research note on Monday, May 5th. Four analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $546.00.

Insider Buying and Selling

In other news, Director M Anne Szostak sold 1,260 shares of the business's stock in a transaction that occurred on Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total transaction of $645,548.40. Following the transaction, the director now directly owns 1,801 shares in the company, valued at $922,724.34. The trade was a 41.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.98% of the stock is currently owned by insiders.

IDEXX Laboratories Stock Down 0.8%

IDEXX Laboratories stock traded down $4.22 during mid-day trading on Friday, reaching $522.70. 411,464 shares of the company were exchanged, compared to its average volume of 649,556. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $530.73. The business has a fifty day moving average of $473.11 and a 200 day moving average of $444.30. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. The firm has a market cap of $42.04 billion, a P/E ratio of 48.99, a PEG ratio of 3.41 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.93 by $0.03. The company had revenue of $998.43 million during the quarter, compared to analyst estimates of $998.25 million. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. The firm's quarterly revenue was up 3.6% on a year-over-year basis. During the same quarter last year, the business posted $2.71 EPS. Research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.